Bexion Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of BXQ-350 in Patients with Advanced Solid Tumors
FOR IMMEDIATE RELEASE Covington, KY - Bexion Pharmaceuticals, Inc. (Bexion) announces the start of a Phase 1b study of BXQ-350, an open-label study in adult patients with advanced solid tumors. The company announced in September 2017 [...]
Promising new drug targets solid tumors; phase 1A clinical trials successfully completed By Michele Sequeira — October 02, 2017 Categories: Cancer Center Patient Care Albuquerque, NM — The University of New Mexico Comprehensive Cancer Center played a key role in the [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857